Vincent Yan (@VincentKCYan) header
Vincent Yan (@VincentKCYan) profile picture

Postdoc Fellow in Pharmacoepidemiology @HkuPharm | Pharmacist | #cardiovascular #mentalhealth #datascience #programming

Hong Kong
Joined August 2022
Vincent Yan retweeted
Our latest study has been published in @AnnalsofIM. The DOAC group had a higher 1-year risk of stroke than warfarin in Asian AF-MS patients. We also found that rivaroxaban increased the risk of stroke, while non-rivaroxaban DOACs did not. Full paper: acpjournals.org/doi/10.7326/…
1
28
1
14
741
I am glad to share our published paper in Value in Health Regional Issues on patient preferences for lipid-lowering agents in hypercholesterolemia using a DCE. These insights support more patient-centered lipid-lowering strategies and improve adherence. lnkd.in/gdVzNh8P
1
6
7
72
Vincent Yan retweeted
Our research letter on @JInternMed shows that #GLP1RA therapy exhibits no significant difference in #depression risk across diverse populations, though routine clinical monitoring of patients' #mental health is recommended to ensure safe prescribing. onlinelibrary.wiley.com/doi/…
1
12
12
476
Vincent Yan retweeted
Excited to share our latest study in @TheLancet: long-acting injectable antipsychotics (LAIAs) are more effective than oral and equally safe for older people, except for higher risk of EPS with typical LAIAs, but not with atypical LAIAs. @Esther_CSMPRHKU thelancet.com/journals/lanps…
40
1
21
1,098
Vincent Yan retweeted
Our @JACCJournals paper found that #statin use for primary #prevention was associated in all-cause #mortality and major #CVD reductions with a very low risk of adverse effects among #T1DM adults, guiding personalized statin #treatment decisions in T1DM. sciencedirect.com/science/ar…
2
43
29
1,022
Our multinational network cohort study shows that extensive multi-organ involvement of post-COVID-19 condition over the short-term period and the subside in risk for most complications over the medium- and long-term. journals.sagepub.com/doi/10.…
38
18
962
Thanks a lot for the professional editing from the Lancet Group. Our podcast about biologics access and recent policy development in Asia Pacific is now on air from the Lancet Rheumatology and the Lancet Regional Health Western Pacific. buzzsprout.com/1907323/episo…
24
1
14
909
Read the full paper here: sciencedirect.com/science/ar…
21
4
614
Vincent Yan retweeted
Our latest multinational study on trends in survival after #Dementia diagnosis has just been published with @SpringerNature in @CommsMedicine Read here: rdcu.be/eocfU @Ian_HKU @ChuiCeline @KennethKCMan @Knappem @GloW_hk
52
23
1,129
Our study, the largest conducted to date examining various classes of antihypertensive drugs and dementia risk. We found a lower risk of all-cause dementia with ARBs compared to ACE inhibitors. Hong Kong, UK, Sweden, and Australia data included. doi.org/10.1093/ageing/afaf1…
6
58
2
41
4,931
Country Income, Gini Index, Disease Burden and Universal Health Coverage, which one you would expect as the driving factor for the access of WHO essential cancer medicine? Read our fresh online paper on Lancet Oncology.sciencedirect.com/science/ar… @hkumed @HkuPharm @CSMPR_HKUPharm
34
20
736
I am honored to be the Founding President of ISPE HK Student Chapter, a student-led initiative to promote knowledge exchange and networking in HK #PharmacoEpi community Many thanks to our advisors @ChuiCeline @Esther_CSMPRHKU and team Eunice, Jack, Tina for their support
🚀 We're thrilled to announce the official launch of the International Society for Pharmacoepidemiology Hong Kong Student Chapter (ISPE HKSC)! Join our community! Follow us for networking, mentorship, and hands-on workshops and more! 🙌🏻 forms.gle/guxrUtmYEW9DNGqw6
1
1
121
Vincent Yan retweeted
In this study Vincent Ka Chun Yan and colleagues investigate the prescribing trends of indapamide and the long term comparative effectiveness of modified release versus immediate release indapamide. Read the full research article here: bit.ly/4bnRjc6
4
5
480